Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tranzyme Pharma has begun the Phase 2b, 12-week trial of oral, gastrointestinal (GI) motility drug candidate, TZP-102 in diabetic patients.
Subscribe to our email newsletter
TZP-102 is an orally-administered promotility agent used to treat diabetic gastroparesis as it targets the ghrelin receptor, which plays a direct role in the stimulation of GI motility.
The Phase 2b double-blind trial is intended to evaluate two dose levels of TZP-102 and placebo administered orally, once daily, for 12 weeks in diabetic patients with a history of moderate to severe symptoms of gastroparesis.
The company expects to dose nearly 200 patients in the US and Europe across three treatment arms including10mg or 20mg doses of TZP-102 or placebo.
The data is likely to be released by 2012 end.